ofloxacin has been researched along with Lung Diseases, Obstructive in 12 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
Lung Diseases, Obstructive: Any disorder marked by obstruction of conducting airways of the lung. AIRWAY OBSTRUCTION may be acute, chronic, intermittent, or persistent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a double-blind study of 137 patients with exacerbation of chronic bronchitis and chronic obstructive lung disease, the efficacy and safety of ofloxacin was compared with that of trimethoprim-sulfamethoxazole (TMP/SMX)." | 9.07 | Double-blind comparative study of ofloxacin (Hoe 280) and trimethoprim-sulfamethoxazole in the treatment of patients with acute exacerbations of chronic bronchitis and chronic obstructive lung disease. ( Boye, NP; Gaustad, P, 1991) |
| "We made an open, noncomparative evaluation of ofloxacin, 400 mg orally bid for 10 days, in 98 subjects with community-acquired pneumonia or pathogen-confirmed bronchitis." | 5.07 | Oral ofloxacin therapy for lower respiratory tract infection. ( Farber, MO; Gentry, LO; Lipsky, B; Rodriguez-Gomez, G; Tucker, B, 1992) |
| "Two different oral ofloxacin regimens, daily single-dose treatment with 200 mg (Regimen I) and every two week multidose treatment with 3 x 200 mg/day (Regimen II), were compared to evaluate the efficacy of quinolone regimens in controlling acute exacerbations of chronic respiratory tract infections." | 5.07 | Once daily versus every two week multidose ofloxacin in patients with acute exacerbations of chronic respiratory disease. ( Watanabe, A, 1991) |
| "In a double-blind study of 137 patients with exacerbation of chronic bronchitis and chronic obstructive lung disease, the efficacy and safety of ofloxacin was compared with that of trimethoprim-sulfamethoxazole (TMP/SMX)." | 5.07 | Double-blind comparative study of ofloxacin (Hoe 280) and trimethoprim-sulfamethoxazole in the treatment of patients with acute exacerbations of chronic bronchitis and chronic obstructive lung disease. ( Boye, NP; Gaustad, P, 1991) |
| "Ambroxol does not increase ofloxacin concentrations in bronchial tissue because high concentrations are already present in the lung." | 2.68 | Evaluation of the effects of ambroxol on the ofloxacin concentrations in bronchial tissues in COPD patients with infectious exacerbation. ( Bouvet, O; Bressolle, F; Chanez, P; Fabre, D; Galtier, M; Godard, P; Michel, FB; Paganin, F, 1995) |
| "Ofloxacin was found to be a safe, well-tolerated therapeutic agent, which was as effective clinically as amoxicillin or erythromycin and with an advantage of less frequent administration." | 2.66 | Ofloxacin in community-acquired lower respiratory infections. A comparison with amoxicillin or erythromycin. ( Garcia, JG; Griffith, DE; Kohler, RB; Stocks, JM; Wallace, RJ, 1989) |
| " This method was applied to the pharmacokinetic study of ofloxacin in 24 chronic obstructive pulmonary disease patients." | 1.29 | A reproducible, simple and sensitive HPLC assay for determination of ofloxacin in plasma and lung tissue. Application in pharmacokinetic studies. ( Bouvet, O; Bressolle, F; Fabre, D; Galtier, M; Kinowski, JM; Paganin, F, 1994) |
| " Dosing modifications and an awareness of possible central nervous system adverse effects are warranted." | 1.29 | Association of a Tourette-like syndrome with ofloxacin. ( Reagan, DR; Thomas, RJ, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (25.00) | 18.7374 |
| 1990's | 7 (58.33) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jones, JW | 1 |
| Kiefe, CI | 1 |
| Fabre, D | 2 |
| Bressolle, F | 2 |
| Kinowski, JM | 1 |
| Bouvet, O | 2 |
| Paganin, F | 2 |
| Galtier, M | 2 |
| Chanez, P | 1 |
| Godard, P | 1 |
| Michel, FB | 1 |
| Thomas, RJ | 1 |
| Reagan, DR | 1 |
| Ho, PL | 1 |
| Tse, WS | 1 |
| Tsang, KW | 1 |
| Kwok, TK | 1 |
| Ng, TK | 1 |
| Cheng, VC | 1 |
| Chan, RM | 1 |
| Gentry, LO | 1 |
| Lipsky, B | 1 |
| Farber, MO | 1 |
| Tucker, B | 1 |
| Rodriguez-Gomez, G | 1 |
| Watanabe, A | 1 |
| Boye, NP | 1 |
| Gaustad, P | 1 |
| Stapel, A | 1 |
| Freymann, H | 1 |
| Ruge, W | 1 |
| Stocks, JM | 1 |
| Wallace, RJ | 1 |
| Griffith, DE | 1 |
| Garcia, JG | 1 |
| Kohler, RB | 1 |
| Meek, JC | 1 |
| Maesen, FP | 1 |
| Davies, BI | 1 |
| Wijnands, WJ | 1 |
| Vree, TB | 1 |
| Baars, AM | 1 |
| van Herwaarden, CL | 1 |
6 trials available for ofloxacin and Lung Diseases, Obstructive
| Article | Year |
|---|---|
Evaluation of the effects of ambroxol on the ofloxacin concentrations in bronchial tissues in COPD patients with infectious exacerbation.
Topics: Administration, Oral; Aged; Ambroxol; Anti-Infective Agents; Biopsy; Bronchi; Bronchoscopy; Chromato | 1995 |
Oral ofloxacin therapy for lower respiratory tract infection.
Topics: Administration, Oral; Adult; Age Factors; Aged; Aged, 80 and over; Bronchitis; Drug Administration S | 1992 |
Once daily versus every two week multidose ofloxacin in patients with acute exacerbations of chronic respiratory disease.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Bacterial Infections; Bronchiectasis; Bronchitis; Chr | 1991 |
Double-blind comparative study of ofloxacin (Hoe 280) and trimethoprim-sulfamethoxazole in the treatment of patients with acute exacerbations of chronic bronchitis and chronic obstructive lung disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bronchitis; Chronic Disease; Double-Blind Method; Female | 1991 |
[Significance of ofloxacin for the treatment of infection-exacerbated chronic obstructive lung disease].
Topics: Aged; Confusion; Humans; Lung Diseases, Obstructive; Middle Aged; Ofloxacin; Respiratory Tract Infec | 1990 |
Ofloxacin in community-acquired lower respiratory infections. A comparison with amoxicillin or erythromycin.
Topics: Adult; Amoxicillin; Bronchitis; Erythromycin; Female; Humans; Lung Diseases, Obstructive; Male; Midd | 1989 |
6 other studies available for ofloxacin and Lung Diseases, Obstructive
| Article | Year |
|---|---|
Anthrax attacks and practice patterns: a learning opportunity for health care systems.
Topics: Acute Disease; Alabama; Ambulatory Care Facilities; Anthrax; Antibiotic Prophylaxis; Bioterrorism; C | 2002 |
A reproducible, simple and sensitive HPLC assay for determination of ofloxacin in plasma and lung tissue. Application in pharmacokinetic studies.
Topics: Chromatography, High Pressure Liquid; Drug Stability; Humans; Lung; Lung Diseases, Obstructive; Oflo | 1994 |
Association of a Tourette-like syndrome with ofloxacin.
Topics: Aged; Anti-Infective Agents; Humans; Lung Diseases, Obstructive; Male; Ofloxacin; Tourette Syndrome | 1996 |
Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Case-Control Studies; Drug Resistance, Microbial; Fe | 2001 |
A prospective study of ofloxacin in acute exacerbations of chronic respiratory disease associated with Pseudomonas aeruginosa.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Female; Humans; Lung Diseases, Obstructive; Male; Middle | 1989 |
The influence of the 4-quinolones ciprofloxacin, pefloxacin and ofloxacin on the elimination of theophylline.
Topics: Aged; Anti-Infective Agents; Ciprofloxacin; Female; Humans; Lung Diseases, Obstructive; Male; Metabo | 1987 |